Cancer name Ovarian Cancer
Cancer Type OV
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment SC144
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature Survivin
Official Symbol BIRC5
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Survivin and MMP-7 were the most sensitive to SC144 treatment; theirabundance was significantly decreased during the first 24hours, whereas cyclin D1, Bcl-XL, Bcl-2, andApe1/Ref-1 expression started to decrease after 24 hours.
PMID 23536726
Title Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer